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Abstract
Human onchocerciasis, caused by the filarial nematode Onchocerca volvulus, is controlled almost exclusively by the drug
ivermectin, which prevents pathology by targeting the microfilariae. However, this reliance on a single control tool has led
to interest in vaccination as a potentially complementary strategy. Here, we describe the results of a trial in West Africa to
evaluate a multivalent, subunit vaccine for onchocerciasis in the naturally evolved host-parasite relationship of Onchocerca
ochengi in cattle. Naı ¨ve calves, reared in fly-proof accommodation, were immunised with eight recombinant antigens of O.
ochengi, administered separately with either Freund’s adjuvant or alum. The selected antigens were orthologues of O.
volvulus recombinant proteins that had previously been shown to confer protection against filarial larvae in rodent models
and, in some cases, were recognised by serum antibodies from putatively immune humans. The vaccine was highly
immunogenic, eliciting a mixed IgG isotype response. Four weeks after the final immunisation, vaccinated and adjuvant-
treated control calves were exposed to natural parasite transmission by the blackfly vectors in an area of Cameroon
hyperendemic for O. ochengi. After 22 months, all the control animals had patent infections (i.e., microfilaridermia),
compared with only 58% of vaccinated cattle (P=0.015). This study indicates that vaccination to prevent patent infection
may be an achievable goal in onchocerciasis, reducing both the pathology and transmissibility of the infection. The cattle
model has also demonstrated its utility for preclinical vaccine discovery, although much research will be required to achieve
the requisite target product profile of a clinical candidate.
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Introduction
Onchocerciasis (‘River Blindness’) is recognised as one of the
world’s most important neglected tropical diseases [1]. The first-
stage larva (microfilaria, Mf) of the nematode Onchocerca volvulus
causes debilitating lesions of the eyes and skin [2], with .99% of
the global burden confined to sub-Saharan Africa [3]. Recent
rapid epidemiological mapping of onchocerciasis in central Africa
has determined that the prevalence is 37 million [3], more than
double that estimated in 1995 [4].
Initially, the main tool for onchocerciasis control was the
targeting of riverine breeding sites of the blackfly vector (Simulium
spp.) with larvicides [5]. However, when the anthelminthic drug
ivermectin was donated for human use in 1987, it supplemented
vector control in the original Onchocerciasis Control Programme
(which ceased operations in 2002) and is now the single tool used
for the vast majority of regions covered by the current African
Programme for Onchocerciasis Control and the Onchocerciasis
Elimination Program for the Americas [6]. Indubitably, ivermec-
tin has been extremely successful in controlling onchocerciasis as a
public health problem through annual or semi-annual mass
treatments [7]; however, it also has a number of limitations.
Firstly, ivermectin is a microfilaricidal drug that is not lethal to the
adult worms (i.e., macrofilaricidal) [8]; hence, repeated treatments
are required as the adults can persist in the human host for over 10
years [9]. Secondly, ivermectin is contraindicated in areas of
central Africa that are hyperendemic for another filarial infection,
loiasis, because it can induce a severe post-treatment encephalop-
athy [10]. Thirdly, ivermectin does not always abrogate
transmission, and maintenance of drug distribution for decades
is constrained by economic and logistical hurdles, particularly in
regions of civil unrest [11]. Finally, there is mounting clinical [12]
www.plosntds.org 1 November 2009 | Volume 3 | Issue 11 | e544and molecular [13] evidence that resistance to ivermectin may be
emerging in certain foci.
Potential complementary control options for onchocerciasis
include a macrofilaricidal drug or a vaccine. The targeting of the
Wolbachia endosymbionts found within worm tissues with antibi-
otics has been shown to be macrofilaricidal in Onchocerca infections
[14,15] and there has been extensive research into this approach
[16]. However, antibiotic chemotherapy is currently not suitable
for mass administration since macrofilaricidal activity requires 4–6
weeks of continuous treatment [15]; shorter regimens are not
effective [17,18]. The ambitious objective of vaccine development
was the focus of the Edna McConnell Clark Foundation’s ‘Oncho
Task Force’ network, which facilitated the development of animal
models for onchocerciasis, as well as characterisation and
production of recombinant antigens and investigations of mam-
malian immune responses to the parasite [19]. With the recent
renewed determination to reduce the global burden of neglected
tropical diseases, there has come awareness that even vaccines
with only partial efficacy could have a major impact in endemic
countries if combined with existing chemotherapeutics [20,21].
Proof-of-principle for vaccination against onchocerciasis in
natural host-parasite relationships has been demonstrated against
O. lienalis in cattle using sonicated Mf [22] and against O. ochengi,
also in cattle, using irradiated infective larvae (L3) [23]. The latter
species is the closest extant relative of O. volvulus [24] and is
transmitted by the same complex of blackfly vectors (S. damnosum
sensu lato) in west and central Africa [25]. Moreover, O. volvulus
and O. ochengi exhibit extensive antigenic cross-reactivity, as
evidenced by the serological recognition of O. volvulus recombinant
antigens by cattle infected with O. ochengi [26], and can generate
cross-protective responses both experimentally [27] and naturally
[25]. Therefore, the bovine O. ochengi system was utilised to
evaluate a recombinant vaccine in a field trial in a hyperendemic
area. The vaccine comprised 8 antigens (table 1), originally
identified in O. volvulus, that were expressed as O. ochengi
Author Summary
River blindness, or onchocerciasis, is caused by a parasitic
worm (Onchocerca volvulus) that is transmitted by blood-
feeding blackflies, which breed in fast-flowing rivers. More
than 37 million people are infected and may experience
visual impairment and/or severe dermatitis. Control of
onchocerciasis is largely dependent on a single drug,
ivermectin. Whilst this is extremely effective at killing the
worms’ offspring (microfilariae) and preventing symptoms,
ivermectin does not eliminate the long-lived adult
parasites or always stop transmission. Consequently,
treatments must be repeated for many years, and drug
resistance may be emerging. Against this background, a
vaccine against onchocerciasis would provide an impor-
tant additional tool to sustain effective control. In this
study, we evaluated eight worm antigens as vaccine
components in cattle, which are often parasitized by O.
ochengi (the closest relative of O. volvulus) in West Africa.
Twelve uninfected animals received all eight antigens and
were exposed to natural transmission of O. ochengi
alongside 13 unvaccinated cattle. After almost two years,
92% of vaccinated animals had acquired adult worms, but
only 58% were positive for microfilariae; whereas 100% of
unvaccinated animals harboured both parasite stages. This
suggests that a vaccine against microfilariae to prevent
development of disease in humans may be achievable.
Table 1. Characteristics of the antigens.
Designation (GenBank
accession no.) Description
Evidence for
protection
b
Optimal
adjuvant
Stage of
expression
Percent highly, poorly, and
non-immunoresponsive calves
a
IgG1
c IgG2
c
OoALT1 (EU573935) Secreted larval acidic
protein, ‘abundant larval
transcript’ [43,44]
Mouse [44,45], human [45] Alum [45] L2,L 3 [43,44] 100, 0, 0 (0, 23, 77) 8, 92, 0 (0, 8, 92)
OoB8* (EU573934) Uncharacterised [45] Mouse, human [45] Alum [45] All [45] 67, 33, 0 (8, 23, 69) 0, 100, 0 (0, 15, 85)
OoRAL2 (EU573933) Uncharacterised [46] Mouse
d, human [46],
chimpanzee [47]
Freund’s
d L3, adult [46] 100, 0, 0 (23, 23, 54) 92, 8, 0 (8, 23, 69)
OoTMY1* (EU573931) Tropomyosin moiety [33] Human [33], jird [38] Freund’s [38] All [33] 100, 0, 0 (54, 46, 0) 67, 33, 0 (15, 31, 54)
OoCPI (EU573930) Cysteine protease inhibitor,
‘onchocystatin’ [48,49]
Mouse, human [45] Alum [45] Egg, L3,L 4, adult [48] 100, 0, 0 (23, 23, 54) 0, 100, 0 (0, 31, 69)
OoB20* (EU573937) Uncharacterised [50] Cow, jird [51] Freund’s [51] Mf, L2,L 3,L 4 [50] 100, 0, 0 (8, 23, 69) 17, 83, 0 (0, 0, 100)
OoFAR1 (EU573932) Fatty acid retinoid-binding
protein [52]
Jird [53], human [40] Freund’s [53] All [53] 100, 0, 0 (23, 23, 54) 100, 0, 0 (0, 31, 69)
OoFBA* (EU573936) Fructose-1,6-bisphosphate
aldolase [34]
Mouse [34] Freund’s [34] All [34] 100, 0, 0 (31, 31, 38) 100, 0, 0 (0, 15, 85)
Notes Mf, microfilaria; L2–4, larval developmental stages.
*These antigens represent truncated polypeptides, not full-length proteins.
aVaccinated calves (n=12) received all eight antigens in separate inoculations with the respective optimal adjuvant; data in parentheses are comparative values for
adjuvant-control animals that received adjuvants only (n=13).
b‘Mouse’ refers to the Onchocerca volvulus L3 chamber model; ‘jird’ to the filarial parasite Acanthocheilonema viteae in its natural rodent host, Meriones unguiculatus;
‘cow’ to O. lienalis in its natural host; ‘chimpanzee’ to experimental infection with O. volvulus; and ‘human’ to serological recognition by putatively immune individuals
from areas endemic for O. volvulus infection.
cHighly, poorly and non-immunoresponsive animals exhibited OD405 nm.1.0, 0.1–1.0, or ,0.1 units (respectively) immediately before natural exposure to infection. Prior
correction for non-specific binding was achieved by subtraction of OD405 nm for a pool of negative control sera (obtained from 6 unexposed calves that received
neither antigens nor adjuvants).
dD. Abraham, unpublished data.
doi:10.1371/journal.pntd.0000544.t001
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research by laboratories within the Oncho Task Force, which used
two main criteria: efficacy against filariae in animal models and/or
recognition by ‘putatively immune’ sera, obtained from humans
who remained apparently uninfected despite intensive natural
exposure to O. volvulus transmission.
Methods
Animals, field site and ethics
Pregnant cows (Bos indicus, Gudali breed) were recruited from
the Adamawa Plateau region of Cameroon, and their calves were
reared from birth in fly-proof accommodation at the Institut de
Recherche Agricole pour le De ´veloppement (IRAD), Regional
Centre of Wakwa, near Ngaounde ´re ´. The calves were divided into
two groups that were matched for age, weight and O. ochengi
infection status of the dam, as determined by presence or absence
of Mf in skin biopsies (table 2). For natural exposure to infection,
animals were grazed on pasture bordering the River Vina du Sud
for 22 months as previously described [23]. This is a hyperen-
demic area for O. ochengi, where the annual transmission potential
has been estimated at 74,000 L3 per animal [25]. All procedures
performed on animals in Cameroon were equivalent to those
authorised by a Home Office Project Licence (Animals [Scientific
Procedures] Act 1986) for related work on cattle in the UK. The
study was approved by the Ethics Committee of the Regional
Centre of Wakwa, IRAD, and authorised by the Regional
Programmes Committee of IRAD before experimental work
began.
Recombinant antigens
The eight O. volvulus antigens selected for the vaccine trial were
identified in an O. ochengi L3-stage Lambda ZAP Express
(Stratagene) cDNA library using a standard plaque screening
technique (ECL Probe-Amp Kit, Amersham Pharmacia Biotech).
Briefly, probes were PCR-labelled with fluorescein using the O.
volvulus cDNA clones as template. The O. ochengi l-phage plaques
were hybridized with the labelled probe to identify the orthologous
O. ochengi cDNA phage clones, which were then isolated and
amplified by PCR. Sequences were verified using a dRhodamine
Terminator Cycle Sequencing Kit (Applied Biosystems) on a 310
Genetic Analyzer instrument (Applied Biosystems). The PCR
products were sub-cloned (in the appropriate reading frame) into
an expression vector incorporating a N-terminal polyhistidine tag
(pRSET [Invitrogen] or pJC40 [ATCC]), and the purified
plasmids were transformed into BL21(DE3) Escherichia coli cells
(Invitrogen) for recombinant protein expression. Following
analysis by SDS-PAGE, 25 mg of each recombinant fusion
protein was purified by metal chelation chromatography (His?Bind
Purification Kit, Novagen) according to the manufacturer’s
instructions. The purified recombinant proteins were dialyzed
against 16phosphate-buffered saline (PBS) and quantified using a
bicinchoninic acid protein assay (Pierce).
Vaccination schedule
Each calf in the vaccinated group received all 8 recombinant
antigens as separate injections (a primary immunisation followed
by two boosters at 4-week intervals; table 3) in the respective
optimal adjuvant (table 1). The proteins were solubilised in sterile
PBS, combined with an equal volume of either alum (Imject,
Pierce) or Freund’s complete adjuvant (Sigma; primary vaccina-
tion) followed by Freund’s incomplete adjuvant (Sigma; first
booster) then PBS only (second booster), and mixed for 10 min
until emulsified. To reduce the risk of antigenic competition, each
protein was delivered (50% i.m. and 50% s.c.) in a unique
muscular site adjacent to a draining lymph node (left or right
omotransversarius, triceps, tensor fasciae latae or semitendinosus),
and injections in different adjuvants were staggered by two weeks
to minimise potential interactions (table 3).
Isotype-specific ELISA
At predetermined intervals, blood was collected by jugular
venepuncture and serum was stored at 220uC prior to transport to
the UK on refrigerant gel. To reduce non-specific background
signals, sera (10% [vol/vol]) were pre-absorbed against E. coli
extract (2 mg/ml protein, Promega) in blocking solution (20%
[vol/vol] soya milk, 10 mM Tris-hydrochloride, pH 8.5; 150 mM
sodium chloride, 0.1% [vol/vol] ‘Tween’-20) for 2 h at ambient
temperature, followed by overnight incubation at 4uC. Each stage
of the assays was optimised independently by checkerboard
titration using positive and negative sera pools, obtained from
Gudali cattle with patent O. ochengi infection (n=9) or 13-week-old
Gudali calves reared from birth in fly-proof accommodation
(n=6), respectively.
Microtitre plates (MaxiSorp, Nunc) were coated with recombi-
nant antigen in carbonate buffer (15 mM sodium carbonate,
35 mM sodium bicarbonate, pH 9.6) for 24 h (4uC), blocked
overnight (4uC) and incubated for 2 h (ambient) with sera diluted
in blocking solution. Horseradish peroxidase-conjugated, sheep
anti-bovine IgG1 or IgG2 (both obtained from Serotec) was
diluted to 0.2 mg/ml in wash buffer (i.e., blocking solution without
soya milk) and applied for 2 h (ambient) followed by addition of
substrate-chromogen (0.3 mg/ml diammonium 2,29-azino-
Table 2. Experimental animals.
Group (n R,n=)
a
Median (range)
age, weeks
b
Median (range)
weight, kg
b
Dam status
(% infected)
c
Vaccinated (5, 7) 25 (21–30) 85 (56–120) 75
Adjuvant control (3, 10) 25 (21–30) 96 (64–124) 77
aBoth groups originally contained 20 animals, but a total of 15 calves died of
causes unrelated to onchocerciasis (predominantly trypanosomiasis) during
the first six months of exposure.
bAt the time of exposure.
cAs determined by microscopic examination of skin biopsies for microfilariae.
doi:10.1371/journal.pntd.0000544.t002
Table 3. Schedule of injections.
Injection schedule (weeks)
a Dose per antigen (mg)
b Vehicle
b
14 500 FCA
12 500 Alum
10 250 FIA
8 250 Alum
6 250 PBS
c
4 250 Alum
Notes FCA, Freund’s complete adjuvant; FIA, Freund’s incomplete adjuvant;
PBS, phosphate-buffered saline.
aPreceding natural exposure to infection.
bAdjuvant controls received an equivalent volume of PBS instead of antigen, in
combination with vehicle, following an identical schedule to vaccinated
animals.
cFinal injection in the Freund’s series.
doi:10.1371/journal.pntd.0000544.t003
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drogen peroxide in 50 mM sodium citrate buffer, pH 4.0). All
washes were performed using a SkanWasher-400 automated
instrument (Molecular Devices) and OD was measured at 405 nm
on an MRX microplate reader (Dynex Technologies). Plates were
only accepted if OD405 nm for positive control sera lay within 10%
of a predetermined standard, and sample readings were corrected
by subtraction of negative control values prior to analysis.
To validate comparisons between IgG1 and IgG2 levels, a
commercial bovine immunoglobulin reference serum (Bethyl
Laboratories) was used to coat microtitre plates with known
concentrations of IgG1 and IgG2 (0.006-12 mg/ml). Over this
range, equivalent IgG concentrations produced OD405 nm with a
divergence of ,25%. Thus, OD405 nm was indicative of the
relative concentrations of IgG1 and IgG2 and did not simply
reflect differential avidity of the specific conjugates.
Parasitology
At quarterly intervals from 6 months post-exposure (mpe),
animals were assessed by palpation for intradermal nodules
(containing adult worms); the positions of which were marked in
situ with tattoo ink and recorded on a ‘hide map’. Triplicate skin
biopsies were obtained at the same time-points and Mf densities
were determined by microscopy as previously described [28]. At
the termination of the experiment, palpation for nodules was
performed by an individual blinded to the treatment groups. All
nodules were removed under local anaesthesia over a period of
several weeks (for welfare reasons) and dissected in PBS to release
adult male worms from the female mass. The males were counted
and their lengths measured, and the female was examined
microscopically for developing embryos or Mf in the uteri
(gravidity).
Statistical analysis
All analyses were performed using SPSS software (v. 15.0; SPSS
Inc.), and P,.05 was the critical threshold unless otherwise
specified. For parasitological data, frequencies were compared
using relative risk estimates and Fisher’s exact tests in the crosstabs
procedure, and medians were analysed by Mann-Whitney U tests
with exact significance. For serological data, animals were
categorised as highly, poorly, or non-immunoresponsive according
to cut-offs of .1.0, 0.1–1.0, or ,0.1 OD405 nm units (respectively)
for sera collected immediately before natural exposure to infection.
If a treatment group’s responses to an antigen were in a single
category, further discrimination was achieved using a cut-off at the
50
th percentile. To identify potential interactions between
antibody responses to the recombinant antigens in individual
vaccinated animals, scatter-plots of OD405 nm for antigen-pairs
were inspected visually. An apparent association between
responsiveness categories was analysed by Fisher’s exact test.
The medians of total area-under-curve for antibody responses
were compared using Mann-Whitney U tests with exact
significance, and as 16 individual tests were conducted, the
Bonferroni adjustment for multiple comparisons was applied.
Results
Effect of vaccination on parasitosis
At 22 mpe, the prevalence of dermal Mf in vaccinated animals
was significantly lower (by 42%; P=.015, Fisher’s exact test) than
that observed in adjuvant-control animals (table 4). In contrast,
vaccination had no significant effect on adult worm burdens, as
measured by nodule load, total worm recovery, number of males,
or number of gravid females (table 4). Moreover, the length of
male worms was not affected significantly by vaccination (data not
shown). Despite the reduced prevalence of Mf in vaccinated cattle,
median microfilarial density was equivalent to that for adjuvant-
control animals (table 4). There was no statistically significant
relationship between positive skin biopsies in calves at the
termination of the experiment and positive status of dams
(table 2) for Mf before calving (relative risk, 0.98; 95% C.I.,
0.64–1.52).
Antibody responses to recombinant antigens
All vaccinated animals responded with both IgG isotypes to all 8
antigens (defined as an OD405 nm value .0.1 units above the
negative control baseline) immediately prior to field exposure
(table 1), a time-point that corresponded to 4 weeks after the final
immunisations (table 3). For IgG1, all vaccinated animals were
highly immunoresponsive (OD405 nm.1.0) to all antigens except
OoB8, which was strongly recognised by only two-thirds of
immunised calves (table 1). Animals with poor IgG1 responses to
OoB8 tended to exhibit higher IgG1 levels for OoFBA, but this
association was not statistically significant (P=.061, Fisher’s exact
test). In all cases, IgG2 levels were lower than for IgG1, although
.90% of vaccinated animals showed strong recognition of
OoRAL2, OoFAR1 and OoFBA with this isotype (table 1).
The majority of adjuvant-control animals did not recognise any
of the antigens, with the notable exception of IgG1 responses to
OoTMY1 (54% high responders, table 1). Strong IgG1 responses
Table 4. Prevalence and burden of O. ochengi in vaccinated and control animals at 22 months post-exposure.
Vaccinated Adjuvant control P
a
Frequency of nodule-positive animals 11/12 13/13 0.480
b
Frequency of Mf-positive animals 7/12 13/13 0.015
b
Median (range) no. of nodules 9.5 (0–19) 14.0 (1–45) 0.263
c
Median (range) no. of male worms 12.0 (0–26) 13.0 (1–34) 0.716
c
Median (range) no. of gravid females 3.5 (0–7) 3.0 (1–9) 0.716
c
Median (range) total worm recovery 21.5 (0–36) 27.0 (2–79) 0.412
c
Median (range) Mf density per 100 mg skin 14.0 (0.0–2757.4) 17.5 (0.0–317.2)
d 0.657
c
aBold type indicates statistical significance at the P,.05 level.
bFisher’s exact test.
cMann-Whitney U test.
dOne animal was negative at this time-point but had been positive on prior occasions.
doi:10.1371/journal.pntd.0000544.t004
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animals, whereas high IgG2 levels in this group were restricted to
1–2 animals recognising OoTMY1 and OoRAL2 (table 1).
The total area-under-curve was calculated for IgG1 and IgG2
responses at 0, 4 and 21 mpe, and plotted separately for adjuvant-
control animals, vaccinated cattle that became patent, and
vaccinated animals that were protected from patent infection
(figure 1). In general, antibody levels in the vaccinated group
peaked at 0–4 mpe; moreover, there was very little (if any)
response above baseline to any of the antigens in adjuvant-control
cattle following exposure (data not shown). The only marked
difference in area-under-curve between patent and non-patent
vaccinated animals was observed with the IgG2 response to
OoTMY1 (figure 1), with a higher median level exhibited by
protected cattle (Mann-Whitney U test, P=.048). However, this
was not statistically significant after Bonferroni adjustment for 16
comparisons (corrected critical P=.003).
Discussion
This study represents the first field trial of a recombinant
antigen vaccine against onchocerciasis, and builds upon our
preceding evaluation of an irradiated L3 vaccine against O. ochengi
that induced significant protection against natural field challenge
[23]. With the recombinant vaccine in the current study, the
prevalence of microfilaridermia (i.e., patent infection) was 42%
lower than in control animals, whereas the irradiated vaccine
induced 67% protection against patency and also significantly
reduced the number of gravid female worms and microfilarial
density in vaccinated cattle [23]. In addition, immunisations using
sonicated O. lienalis Mf conferred 97% protection against
experimental challenge with homologous Mf in cattle that did
not harbour adult parasites [22]. However, a vaccine composed of
native parasite material is very unlikely to be produced for human
use because of the quantities required, the necessity for cryogenic
storage and the infectious risks associated with biological material
recovered directly from the host.
The observed protective efficacy against Mf in the current
experiment, with no significant effect on the adult stage, is
noteworthy. It is possible that the reduction in patent infections in
vaccinated animals was secondary to sub-lethal effects on
reproduction of the adult parasites [29], although this seems
unlikely as there was no apparent abrogation of embryogenesis in
female worms. However, since five of the vaccine antigens are
expressed in Mf (table 1), the direct targeting of this stage by the
immune response is entirely plausible and appears to have
occurred without demonstrable vaccine-mediated inhibition of
L3 development.
A vaccine against Mf might not only be less technically
challenging to develop than a prophylactic vaccine directed
against L3, but could be almost as beneficial to the affected
population if pathology was ameliorated and transmission to the
vector prevented. Conversely, an anti-Mf vaccine might be
associated with a greater risk of inducing immunopathology,
particularly as hyper-reactive onchocerciasis (Sowda) is charac-
terised by an aggressive immune response against Mf [30]. This is
a hypothetical consideration, but one that would need to be
addressed rigorously during clinical testing of any vaccine
candidate in onchocerciasis. Whilst Sowda is relatively uncommon
in most endemic foci, individuals at increased risk of developing
hyper-reactivity to Mf could be identified by genetic screening,
since this condition is associated with particular polymorphisms
[31,32]. Moreover, the innate immune responses to Wolbachia
endobacteria that trigger dermal and ocular pathology in
generalised onchocerciasis are a result of the death of Mf in
significant numbers [30]; this could be prevented if a vaccine
blocked the migration of Mf into the skin and eyes.
The logistic challenges associated with use of a large animal
model under tropical field conditions, and the long duration of
natural exposure required to test protection (,2 years), necessi-
tated a multivalent approach in which all vaccinated animals were
inoculated with all of the most promising candidate antigens
identified in previous studies. Careful design was implemented to
diminish competitive inhibition between immune responses by
separating the inoculations both anatomically and temporally;
consequently, the immunised animals exhibited good immunor-
esponsiveness to the eight antigens at the levels of IgG1, IgG2, or
both isotypes, with little evidence of significant antigen competi-
tion. In most cases, specificity of the bovine serological responses
was high, although a large proportion of adjuvant-control animals
recognised OoTMY1 and OoFBA. Both tropomyosin [33] and
fructose-1,6-bisphosphate aldolase [34] are highly conserved
proteins, and cross-reactive antibodies could have been generated
by co-infections with gastrointestinal nematodes such as Haemon-
chus placei, Cooperia spp. and Strongyloides papillosus. Indeed, even in
housed cattle in the UK, total IgG responses to recombinant O.
volvulus aldolase were almost indistinguishable between animals
experimentally infected with O. ochengi and uninfected controls
[26].
The disparity between the very high levels of protection
afforded by irradiated parasites and some crude antigen extracts,
as compared with the recombinant antigens in the current study,
Figure 1. Total area-under-curve (OD405 nm) for IgG1 and IgG2
responses to eight Onchocerca ochengi recombinant antigens.
‘Vaccinated, patent’ (n=7) or ‘vaccinated, non-patent’ (n=5) refers to
presence or absence of dermal microfilariae at 22 months post-
exposure, respectively; all adjuvant-control animals had patent infec-
tions (n=13). Area-under-curve was calculated from data obtained at 0,
4 and 21 months post-exposure. Box-and-whisker plots display the
median line, 25
th–75
th IQR (box), highest and lowest values within
1.56 IQR (whiskers), outliers (#; .1.5–3.06IQR) and extreme values
(x; .3.06IQR).
doi:10.1371/journal.pntd.0000544.g001
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eukaryotic proteins, the expression of recombinant nematode
proteins in E. coli can lead to the production of molecules that
exhibit aberrant secondary or tertiary structures, or which lack
important post-translational modifications. For instance, the
Ancylostoma secreted proteins have to be expressed in a eukaryotic
system (Pichia pastoris) in order to attain the conformational
epitopes and catalytic activity of the native protein, and these
characteristics are critical for the immunogenicity of hookworm
vaccines under development [35]. However, all the antigens used
in the current field trial had induced significant protection against
filarial challenge in other models when expressed as recombinant
proteins in E. coli (table 1). Perhaps a more relevant limitation to
our multivalent approach is the possibility that one or more of the
antigens reduced the protective efficacy of the others by the
induction of immunoregulatory pathways. Indeed, the O. volvulus
orthologue of one of the antigens used in the vaccine, OoCPI, can
induce hyporesponsiveness in T-cells [36].
There was no compelling association between the serological
response to any single antigen and protection against patent
infection. However, there was a negative trend (non-significant
after Bonferroni correction for multiple comparisons; a highly
conservative statistical adjustment [37]) between levels of IgG2
against OoTMY1 and detectable Mf. As the orthologous
tropomyosin moiety from O. volvulus has been shown to induce
protection against O. lienalis Mf in a mouse model [38], and anti-
tropomyosin antibodies are inversely correlated with Mf density in
infected humans [33], this antigen warrants further investigation
as a key component of a potential anti-Mf vaccine. This does not
necessarily imply that IgG antibodies are the key effectors of
vaccine-mediated immunity, but levels of IGg1 and IgG2 were
assayed in the current study simply to demonstrate recognition of
individual antigens in the immunised animals. Indeed, a previous
study of bovine antibody responses to recombinant O. volvulus
antigens (in Gudali cattle naturally infected with O. ochengi at the
same field site) reported that neither IgG1 nor IgG2 levels were
clearly associated (positively or negatively) with parasite burden
[39]. Further insights into the role of OoTMY1 and the other
antigens might have been revealed by complementary analyses of
IgE levels, lymphoproliferation and eosinophilia [40,41]. It should
be noted that OoTMY1 was delivered in Freund’s adjuvant
because this had been used in a prior vaccination experiment in
jirds, which demonstrated significant protection against a
challenge infection with Acanthocheilonema viteae [38]. As Freund’s
adjuvant is not licensed for human use, future trials should
consider the inclusion of an alternative adjuvant that could
facilitate Th1-like responses, such as CpG oligodeoxynucleotides
[42], which may be close to regulatory approval.
In conclusion, we have demonstrated for the first time under
field conditions that in a natural host-Onchocerca relationship, it is
possible to significantly reduce the frequency of infections that
attain full patency using a recombinant vaccine. The next phase of
vaccine design for onchocerciasis will require the separate
evaluation of individual vaccine candidates (particularly tropomy-
osin) to determine whether the multivalent approach is necessary
to achieve protection. The cattle model, although logistically
challenging and relatively costly, is far less complex and expensive
than are clinical trials in humans. In this field trial and others
[14,17,23], the O. ochengi system has filled a critical niche between
laboratory studies in rodent models (that are unnatural hosts of
Onchocerca parasites) and field evaluation of onchocerciasis control
in human populations. Our study opens up the prospect of
specifically targeting the Mf stage by vaccination, which in
conjunction with currently available chemotherapy, could ensure
that the impressive achievements of onchocerciasis control are
sustained and extended for the decades to come.
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